APERI PHARMACEUTICALS

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.